a home group 2016 - medical dermatology society€¦ · a home group update 2016 eric l. simpson,...
TRANSCRIPT
A HOME Group Update 2016
Eric L. Simpson, MD, MCRProfessor, Dermatology
Oregon Health & Science UniversityPortland, OR USA
Overview
• The problem• Core outcome sets in medicine• HOME and the HOME roadmap• Progress to date• Future plans
Outcome measures – a real mess• Too many – at least 20 named scales
• Many not tested at all (Charman C, JID 2003)
• Data synthesis and comparison difficult
• 40–62% of publications had at least one primary outcome changed (Dwan et al, PLoS ONE 2008)
Schmitt J, Langan S, Williams HC. What are the best outcome measurements for atopic eczema? A systematic review JACI 2007;120:1389-98.
What we need are core outcomes that are used in all trials
SCORADEASI
SASSAD
IGA
TISSSS
POEM
DLQI
SKINDEX
BCSS
ADAM
ADQADASIW‐AZS
VAS
5‐D
QOLIAD
SCORAD
Core Outcome Sets in Medicine
• Agreed‐upon minimum set of outcomes for all trials
• Does not preclude the use of other outcomes• Should be:
– Meaningful to patients– Relevant to those making decisions about health care– Appropriate to setting
• Need to be valid, reliable, sensitive to change, easy to use
Williamson, et al. Developing core outcome sets for clinical trials: issues to consider. Trials, 2014.
Overview
• The problem• Core outcome sets in medicine• HOME and the HOME roadmap• Progress to date• Future plans
Core Outcome Set Groups• IMMPACT‐ pain• WOMBAT – women’s health• PROFANE‐ prevention of falls• EWMA‐ wound management• ADQI‐ nephrology• EUSCLE‐ cutaneous lupus• IMACS‐myositis• PRINTO‐ pediatric rheumatology• OMERACT‐ rheumatology• Asthma, CHF, acute MI, etc…..
Why do we do this?
They say, “don’t touch me‐ I don’t want to get that.”
They say, “don’t touch me‐ I don’t want to get that.”
Don’t want to tackle the day.”
Don’t want to tackle the day.”
I avoided pool parties. Don’t want to go outside.I avoided pool parties.
Don’t want to go outside.
Core Outcome Measures in Effectiveness Trials
www.comet‐initiative.org
• To raise awareness of current problems with outcomes in clinical trials
• To encourage COS development and uptake
• To provide resources to allow practitioners to develop COS, e.g. COMET database
Improvements over time (Kirkham et al, Trials 2013)
Studies reporting full RA COS (%)
WHO/ILARRA COS
EMAguideline
FDAguideline
100
80
60
40
20
1985 1990 1995 2000 2005 2010
0
Mean number of clinical outcomes
6.0
6.5
7.0
0.0
drug studies
non-drug studies
The world of medicine is moving on –what about eczema?
Overview
• The problem• Core outcome sets in medicine• HOME and the HOME roadmap• Progress to date• Future plans
Harmonizing Outcome Measures in Atopic Eczema (HOME)
Hywel Williams (UK) Jochen Schmitt (Germany)
Christian Apfelbacher(Germany)
KimThomas (UK)
PhyllisSpuls
(Netherlands)
Eric Simpson(USA)
MasutakaFurue(Japan)
Harmonizing Outcome Measures in Eczema (HOME)
Epidemiologists
Clinicians
Industry
Regulatory
Patients
HOME IV ConferenceMalmo, Sweden 2015
The HOME RoadmapA Methodological Framework for Developing Core Outcome Sets
J Invest Dermatol, 2014
The HOME Roadmap
Schmitt, et al. J Invest Dermatol 2014
Overview
• The problem• Core outcome sets in medicine• HOME and the HOME roadmap• Progress to date• Future plans
HOME I‐Munich, 2009Schmitt, Williams,et al. BJD, 2010
HOME II‐ Amsterdam, 2011Schmitt, et al. Allergy, 2012
HOME III‐ San Diego, 2013Chalmers, et al. BJD, 2014
HOME IV‐Malmo, 2015In Review, BJD, 2016
Schmitt, et al. Journal Invest Dermatol, 2011
Clinical Signs
SymptomsQuality of Life
Long‐termControl
Consensus Domains to be Measured
Schmitt, et al. Allergy, 2012
Clinical Signs
SymptomsQuality of Life
Long‐termControl
HOME Domains and Instruments
Schmitt, et al. Allergy, 2012
2 SRs+ ConsensusMeeting
JACI, 2007
JACI, 2013
The COSMIN ChecklistConsensus Standards for the Selection of Health Status
Measurement Instruments (Qual Life Rsch 2010)
EpidemiologistPsychologistsStatisticiansClinicians
Reliability Feasibility
ValidityResponsiveness
EASI SCORAD
POEMSASSAD
Jean‐Francois Stalder‐ Hero of HOME III
Clinical Signs
SymptomsQuality of Life
Long‐termControl
Consensus Domains
Schmitt, et al. Allergy, 2012
EASI
2 SRs+ ConsensusMeeting
Disseminationhomeforeczema.org
BJD, 2015
HOME IVMalmo, April 2015
• Reviewed QOL and symptoms SR• POEM picked as instrument for signs• No instrument for QOL agreed upon• Andrew Finlay the hero
Sanna Prinsen, PhD Louise GerbensMD/PhD candidate
Daniel Heinl
Clinical Signs
SymptomsQuality of Life
Long‐termControl
Consensus Domains
EASI POEM
2 SRs+ Consensus
2 SRs+ Consensus
2 SRs 1 SR
DLQI,Skindex,QoLiAD? ????
Future Work
• Dissemination / implementation work for POEM
• HOME V 2017 in Sao Paulo• Achieve consensus on QOL instruments and long‐term control
• Begin a core outcome set for clinical practice/ record keeping
Take Home Points
• International effort needed• Industry are equal partners• Need for systematic approach• Methodologists needed• Establish voting procedures • Third party moderator• Use resources from COMET, CSG‐COUSIN
Summary
• Developing a COS improves research quality
• Leads to more informed decision‐making for you and your patients
• Time‐consuming but extremely rewarding
• Brings together passionate people from around the world interested in your disease state
Join us for HOME V in Brazil 2017!homeforeczema.org
HOME Objectiveshomeforeczema.org
• Develop core sets of outcomes for AD to be used in all clinical trials and clinical settings
• Involve multiple stakeholders including clinicians, researchers, industry, regulatory agencies, and patients
• Open membership
• OMERACT presence and guidance
• Use a systematic and democratic approach based on state of the current evidence